Nicolas Mungo, MD
Endocrinology, Diabetes & Metabolism · Brookfield, WINPI 1245627991
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,566 of the $13,585 with a category attached, or 63.1%. Amgen accounts for 74.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $9,284, 6.1 times the $1,529 reported in 2019.
Across 101 payments — averaging $134.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- Novo Nordisk$2K
- Halozyme Inc$221
- Abbott$217
- Lilly USA, LLC$196
- Corcept Therapeutics$151
- plus $676 from 8 others
What the payments were for
- Speaking & faculty fees$8,56663%
- Travel & lodging$1,97515%
- Food & beverage$2,84621%
- Education$1991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $10,125 |
| Novo Nordisk | 30 | $1,999 |
| Halozyme Inc | 6 | $221 |
| Abbott | 8 | $217 |
| Lilly USA, LLC | 9 | $196 |
| Corcept Therapeutics | 6 | $151 |
| AstraZeneca | 2 | $144 |
| Antares Pharma, Inc. | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $99 |
| Boehringer Ingelheim | 1 | $81 |
| Sequel Med Tech, LLC | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,585 in reported general payments places this provider in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 225 | $275,513 |
| JardianceEmpagliflozin | 84 | $124,447 |
| MounjaroTirzepatide | 104 | $117,516 |
| GenotropinSomatropin | 21 | $53,316 |
| TrulicityDulaglutide | 18 | $32,594 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $24,019 |
| JanuviaSitagliptin Phosphate | 23 | $21,428 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,198 |
| SynthroidLevothyroxine Sodium | 173 | $13,929 |
| XyostedTestosterone Enanthate | 19 | $11,556 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $11,197 |
| Testosterone | 53 | $8,517 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,607 |
| Levothyroxine Sodium | 730 | $6,569 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $6,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,999 | $275,513225 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $196 | $154,130140 claims |
| Boehringer IngelheimJardiance | $81 | $124,44784 claims |
| Antares Pharma, Inc.Xyosted | $138 | $11,55619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Brookfield
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.